Daily single-strength versus thrice-weekly double-strength trimethoprim/sulfamethoxazole for Pneumocystis jirovecii prophylaxis in solid organ transplant recipients: A randomized control trial
Phase 3
Completed
- Conditions
- Adult solid organ transplant recipientsPCP kidney liver heart immunocompromised host
- Registration Number
- TCTR20220720010
- Lead Sponsor
- Faculty of Medicine Ramathibodi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
All adult SOT recipients
Exclusion Criteria
Unwilling to participate
TMP/SMX allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Free from infection 6 months PCR
- Secondary Outcome Measures
Name Time Method Safety 6 months Liver function test